304 related articles for article (PubMed ID: 28492291)
1. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
3. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
4. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
6. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
7. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian R; Weinberg JM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1236-42. PubMed ID: 19876791
[TBL] [Abstract][Full Text] [Related]
8. Evaluating crisaborole as a treatment option for atopic dermatitis.
Ramachandran V; Cline A; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
[TBL] [Abstract][Full Text] [Related]
9. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
10. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
11. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
[TBL] [Abstract][Full Text] [Related]
12. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
[TBL] [Abstract][Full Text] [Related]
14. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Guttman-Yassky E; Hanifin JM; Boguniewicz M; Wollenberg A; Bissonnette R; Purohit V; Kilty I; Tallman AM; Zielinski MA
Exp Dermatol; 2019 Jan; 28(1):3-10. PubMed ID: 30332502
[TBL] [Abstract][Full Text] [Related]
15. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.
Kim M; Del Duca E; Cheng J; Carroll B; Facheris P; Estrada Y; Cha A; Werth J; Bissonnette R; Nocka K; Zang C; Pavel AB; Guttman-Yassky E
J Am Acad Dermatol; 2023 Aug; 89(2):283-292. PubMed ID: 37054814
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Tom WL; Van Syoc M; Chanda S; Zane LT
Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
[TBL] [Abstract][Full Text] [Related]
19. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]